Patients with cancer rarely make clinically inappropriate demands
the ONA take:
According to a new study published in the journal JAMA Oncology, researchers from Abramson Cancer Center and the University of Pennsylvania Perelman School of Medicine in Philadelphia, Pennsylvania, have found that patients rarely push for unnecessary tests and treatments despite physicians' claims that high medical costs are due to patient demands.
For the study, researchers analyzed over 5,000 patient-clinician encounters and found that 440 (8.7%) of those included a patient request or demand for a particular medical medical intervention. Of those, clinicians complied with 365 of the demands after deeming them clinically appropriate.
Of the 50 demands that were not clinically appropriate, clinicians only complied with seven demands. Results showed that 49.1% of demands were for imaging studies, 15.5% for palliative care interventions, 13.6% for laboratory tests, 5.2% for genetic tests, 3.6% for chemotherapy, and less than 1% for proton beam therapy.
In addition, researchers found that patients who had worse relationships with their clinicians and those actively receiving therapy were more likely to make requests or demands.
The findings suggest that patients demands are low and cannot be a key factor of increasing healthcare costs.
Patients rarely push for unnecessary tests and treatments despite physicians' claims that high medical costs are due to patient demands.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|